SEC 13F Intelligence

Trails Edge Capital Partners, LP / IKT

Trails Edge Capital Partners, LP’s Inhibikase Therapeutics Inc Position

Does Trails Edge Capital Partners, LP own Inhibikase Therapeutics Inc (IKT)? Yes8.06M shares worth $14M (+3.10% of its 13F portfolio) as of Q1 2026, up from 6.18M shares the prior filed quarter.

Position Value
$14M
Q1 2026
Shares
8.06M
% of Portfolio
+3.10%
Quarters Held
2
currently held

Position History IKT

Reported value by quarter
Q4 ’25: $13MQ4 ’25Q1 ’26: $14MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20268.06M$14M+3.10%
Q4 20256.18M$13M+3.13%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Trails Edge Capital Partners, LP’s full portfolio or all institutional holders of IKT.